Jump to content

Search the Community

Showing results for tags 'radium223'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 2 results

  1. Radium-223 Radiographic Response: From the Desk of the Associate Editor URO Today Commentary by Andrew Armstrong, MD,ScM, FACP, USA This is a very brief summary of the take away from this study - Follow the link at the bottom of the article for complete details Radium-223 is best used early, before extensive soft tissue metastases occurs, and before the risk of spinal cord compression increases. (Note: Soft tissue disease is not being treated whilst Radium-223 therapy is being administered, it is not effective against soft tissue tumors.) For this reason when being treated with Radium 223 - concurrent use of systemic therapies should be considered in patients with soft tumors/extra-skeletal metastases. Ongoing trials of Radium-223 with enzalutamide, abiraterone, sipuleucel-T, atezolizumab, PARP inhibitors, docetaxel, and other combinations should clarify the optimal combination approaches to controlling bone and soft tissue/visceral metastases. Patients should be followed carefully for pain flare and are likely to need opiate dose titration during therapy. Concurrent care by a palliative care specialist should be strongly considered, given the life expectancy and palliative needs for these patients. Written by: Andrew Armstrong, MD, Dr. Armstrong is Associate Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Associate Director of the Duke Cancer Institute Genitourinary Clinical Research Program Full Text :- Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database https://tinyurl.com/yba4zcpv
  2. Have your say on Xofigo (Radium 223) on the PBS Xofigo® (radium Ra 223), is being considered at the November 2017 Pharmaceutical Benefits Advisory Committee (PBAC) meeting for listing on the Pharmaceutical Benefit Scheme (PBS). There is an opportunity for patients and the prostate cancer community (carers, doctors, organisations etc) to make submission directly to the PBAC. The Australian Advanced Prostate Cancer Support Group Executive Committee will be making a submission. We will post more details of what to say in a submission in mid-September, but if you know what you wish to say now: The preferred method is via an online form. Click this sentence to be taken to the online form. Or via email CommentsPBAC@health.gov.au. The consumer comments are open to until 4 October. Some details of Xofigo treatment are in our YouTube video: Treatment for metastatic prostate cancer in the bones:
  • Create New...